Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

1

Days Left

SSRM

SSR Mining Inc.

Deadline

May 17 2024

Class Period

2/23/22 - 2/27/24

Allegations

(1) defendants materially overstated SSR Mining’s commitment to safety and the efficacy of its safety measures; (2) SSR Mining engaged in unsafe mining practices which were reasonably likely to result in a mining disaster; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times

Class Period

2/23/22 - 2/27/24

Deadline

May 17 2024

Learn More

4

Days Left

CC

The Chemours Company

Deadline

May 20 2024

Class Period

2/10/23 - 2/28/24

Allegations

(1) certain of the Company’s senior executive officers manipulated Free Cash Flow targets as a means to maximize additional cash and stock incentive compensation applicable to executive officers pursuant to the Company’s annual incentive plans and long-term incentive plans; (2) the Company’s accounting practices and procedures, including its internal control over financial reporting, were deficient; and (3) as a result, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

Class Period

2/10/23 - 2/28/24

Deadline

May 20 2024

Learn More

4

Days Left

AGL

agilon health, inc.

Deadline

May 20 2024

Class Period

1/9/19 - 1/9/24

Allegations

(1) touting the Company’s purported visibility into utilization trends and medical costs; (2) failing to disclose increased medical costs that Agilon had incurred prior to and during the class period due to higher utilization of healthcare by MA patients; (3) falsely stating that its incurred-but-not-reported reserve was adequate; (4) making false and misleading statements about the effectiveness of its business model; (5) issuing overly optimistic financial guidance; and (6) issuing risk disclosures that were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities.

Class Period

1/9/19 - 1/9/24

Deadline

May 20 2024

Learn More

5

Days Left

SHLS

Shoals Technologies Group, Inc.

Deadline

May 21 2024

Class Period

5/17/22 - 11/7/23

Allegations

(1) Shoals did not deliver EBOS, electrical balance of system, products that met the highest levels of quality and reliability; (2) Shoals had received reports of exposed copper conduit in EBOS wire harnessess in a large number of solar fields and was aware that a significant portion of its wire harnesses had defects; (3) Shoals would have to incur between $60 million to $185 million in costs to remediate the wire shrinkback issue; and (4) Shoals had understated its cost of revenue by millions of dollars. As a result, defendants’ positive statements about the Company’s financial guidance, business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/17/22 - 11/7/23

Deadline

May 21 2024

Learn More

5

Days Left

PLUG

Plug Power Inc.

Deadline

May 21 2024

Class Period

5/9/23 - 1/16/24

Allegations

(i) Plug overstated its ability and/or efforts to mitigate the negative impacts that, among other things, supply chain constraints and material shortages could have or were having on the Company’s hydrogen business, as well as the sufficiency of its cash and capital to fund its operations; (ii) Plug continued to experience delays related to its green hydrogen production facility build-out plans, as well as in securing external funding sources to finance its growth plans; (iii) Plug downplayed the true scope and severity of all the foregoing when these issues were eventually revealed; (iv) as a result of all the foregoing, Plug also overstated the near-term prospects of its hydrogen production operations, as well as the viability of expanding those operations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

5/9/23 - 1/16/24

Deadline

May 21 2024

Learn More

8

Days Left

EVLV

Evolv Technologies Holdings, Inc.

Deadline

May 24 2024

Class Period

6/28/21 - 3/13/24

Allegations

(1) Evolv materially overstated the efficacy of its products; (2) the lack of effectiveness of Evolv’s products with regard to detecting knives and guns led to an increased risk of undetected weapons entering locations such as schools; (3) Evolv deceived the general public, its customers, and its investors regarding the effectiveness of its products; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

6/28/21 - 3/13/24

Deadline

May 24 2024

Learn More

12

Days Left

BLUE

bluebird bio, Inc.

Deadline

May 28 2024

Class Period

4/24/23 - 12/8/23

Allegations

According to the complaint, on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed AML during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher. Following this news, Blue’s stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.

Class Period

4/24/23 - 12/8/23

Deadline

May 28 2024

Learn More

15

Days Left

LUNA

Luna Innovations Incorporated

Deadline

May 31 2024

Class Period

8/11/23 - 3/25/24

Allegations

(1) Luna Innovations financial statements from August 10, 2023 to the present included false figures as a result of improper revenue recognition; (2) as a result, Luna Innovations would need to restate its previously filed financial statements from August 10, 2023 to November 14, 2023; (3) Luna Innovations lacked adequate internal controls; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

8/11/23 - 3/25/24

Deadline

May 31 2024

Learn More

18

Days Left

HRT

HireRight Holdings Corporation

Deadline

June 3 2024

Class Period

10/28/21 - 11/30/-1

Allegations

(i) HireRight was exposed to customers with significant employment and hiring risk and the Company derived greater revenue growth from existing client hiring than from new client hiring; (ii) as a result, the Company’s revenue growth was unsustainable to the extent that it relied on the stability of its current customers’ hiring and/or the profitability of securing new customers; (iii) accordingly, HireRight had overstated its post- initial public offering business and/or prospects; and (iv) as a result, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

10/28/21 - 11/30/-1

Deadline

June 3 2024

Learn More

26

Days Left

VFS

VinFast Auto Ltd. f/k/a Black Spade Acquisition Co.

Deadline

June 11 2024

Class Period

8/15/23 - 1/17/24

Allegations

(i) VinFast lacked sufficient capital to execute its purported growth strategy; (ii) VinFast would be unable to meet its 2023 delivery targets; (iii) accordingly, VinFast had overstated the strength of its business model and operational capabilities, as well as its post- merger business and/or financial prospects; and (iv) as a result, the offering documents and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Class Period

8/15/23 - 1/17/24

Deadline

June 11 2024

Learn More

26

Days Left

QDEL

QuidelOrtho Corporation f/k/a Quidel Corporation

Deadline

June 11 2024

Class Period

2/18/22 - 4/1/24

Allegations

(a) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) that excess inventories of COVID-19 tests existed throughout the supply chain; (c) that, as a result of (a)-(b) above, QuidelOrtho’s distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) that undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the united states; (e) that, as a result of (a)-(d) above, defendants lacked a reasonable basis for their positive statements about QuidelOrtho’s business, financials, and growth trajectory.

Class Period

2/18/22 - 4/1/24

Deadline

June 11 2024

Learn More

32

Days Left

PERI

Perion Network Ltd.

Deadline

June 17 2024

Class Period

2/9/21 - 4/5/24

Allegations

(1) Perion’s search advertising business was not a reliable and significant growth driver and was in fact in decline; (2) Perion’s long-term relationship with Microsoft and search services agreement would not provide stability for Perion’s search advertising business; (3) there was an increased risk of Microsoft acting to unilaterally change its advertising pricing and mechanisms to the detriment of Perion while the search services agreement was in place; (4) Perion’s AI technology and Microsoft’s investment in ChatGPT, a form of generative AI, would not protect or grow Perion’s search advertising revenue; and (5) based on the foregoing, defendants lacked a reasonable basis for their positive statements about Perion’s search advertising business and related financial results, growth, and prospects.

Class Period

2/9/21 - 4/5/24

Deadline

June 17 2024

Learn More

32

Days Left

ASTS

AST SpaceMobile, Inc.

Deadline

June 17 2024

Class Period

11/14/23 - 4/1/24

Allegations

(1) production of the Company’s five first generation of commercial satellites, Block 1 BlueBird satellites, had been negatively impacted by two suppliers of key subsystems; (2) a result, the Company had not substantially completed the production of the Block 1 BlueBird satellites; (3) as a result, the Company’s five Block 1 BlueBird satellites were not on track to launch in the first quarter of 2024; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/14/23 - 4/1/24

Deadline

June 17 2024

Learn More

33

Days Left

SHCR

Sharecare, Inc.

Deadline

June 18 2024

Class Period

5/10/23 - 3/28/24

Allegations

(1) Sharecare lacked adequate internal controls and; (2) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

5/10/23 - 3/28/24

Deadline

June 18 2024

Learn More

33

Days Left

RIVN

Rivian Automotive, Inc.

Deadline

June 18 2024

Class Period

3/1/23 - 2/21/24

Allegations

(i) Rivian had overstated demand for its products, as well as its ability to withstand negative, near-term macroeconomic impacts; (ii) accordingly, Rivian’s business was experiencing reduced demand and increased customer cancellations as a result of, inter alia, high interest rates; (iii) as a result, Rivian’s order bank had significantly deteriorated; (iv) all the foregoing was likely to, and did, negatively impact the Company’s anticipated earnings and vehicle production targets for 2024; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/1/23 - 2/21/24

Deadline

June 18 2024

Learn More

36

Days Left

GDRX

GoodRx Holdings, Inc.

Deadline

June 21 2024

Class Period

9/23/22 - 11/8/22

Allegations

(1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx’s total prescription transactions revenue (the Company’s primary revenue stream); and (2) Kroger could unilaterally cease accepting GoodRx discounts, cutting off some or all of GoodRx’s revenues for purchases at Kroger’s pharmacies; and (3) as a result, defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Class Period

9/23/22 - 11/8/22

Deadline

June 21 2024

Learn More

39

Days Left

LNC

Lincoln National Corporation

Deadline

June 24 2024

Class Period

11/4/20 - 11/2/22

Allegations

(1) the Company was experiencing a decline in its variable universal life insurance business; (2) as a result, the goodwill associated with the life insurance business was overstated; (3) as a result, the Company’s policy lapse assumptions were outdated; (4) as a result, the Company’s reserves were overstated; (5) as a result, the Company’s reported financial results and financial statements were misstated; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/20 - 11/2/22

Deadline

June 24 2024

Learn More

39

Days Left

CMP

Compass Minerals International, Inc.

Deadline

June 24 2024

Class Period

11/29/23 - 3/22/24

Allegations

(1) Compass Minerals overstated the likelihood that it would be awarded a renewed U.S. Forest Service contract for the use of its proprietary magnesium chloride-based aerial fire retardants for the 2024 fire season, as a result of safety issues presented by its fire retardant; (2) Compass Minerals materially overstated the extent to which testing had confirmed that its fire retardants were safe; and (3) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

11/29/23 - 3/22/24

Deadline

June 24 2024

Learn More

39

Days Left

ADSK

Autodesk, Inc.

Deadline

June 24 2024

Class Period

6/1/23 - 4/16/24

Allegations

(1) Autodesk, Inc. lacked adequate internal controls as a result of issues with its free cash flow and non-GAAP operating margin practices; and (2) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

6/1/23 - 4/16/24

Deadline

June 24 2024

Learn More

40

Days Left

AKRO

Akero Therapeutics, Inc.

Deadline

June 25 2024

Class Period

9/13/22 - 10/9/23

Allegations

(i) approximately 20% of the patients enrolled in the SYMMETRY study, a trial that purportedly tested efruxifermin ("EFX") in patients with nonalcoholic steatohepatitis (“NASH”) -induced cirrhosis, had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study’s design, materially influencing the study’s potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not rule out potential causes of each patient’s cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

Class Period

9/13/22 - 10/9/23

Deadline

June 25 2024

Learn More

43

Days Left

MBUU

Malibu Boats, Inc.

Deadline

June 28 2024

Class Period

11/4/22 - 4/11/24

Allegations

(1) Malibu Boats had engaged in an “elaborate scheme to over manufacture and pump nearly $100 million of its highest priced, highest margin, slow moving boat inventory into fifteen Tommy’s dealerships”; (2) as a result, the Company artificially inflated Malibu’s sales performance, market share, and stock value; (3) the Company was withholding certain incentives and rebates from its dealers; (4) as a result of the foregoing, the Company faced substantial risk of litigation from one of its top dealers, Tommy’s; (5) the Company’s CEO departed due to his role in this scheme; and (6) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/4/22 - 4/11/24

Deadline

June 28 2024

Learn More

46

Days Left

GL

Globe Life Inc. f/k/a Torchmark Corporation

Deadline

July 1 2024

Class Period

5/8/19 - 4/10/24

Allegations

According to the complaint, throughout the Class Period, Globe Life reported consistent premium revenue growth at the Company, led by consistent premium revenue growth at American Income Life Insurance Company (“AIL”). The Company also represented that its employees adhered to a code of conduct that expressly prohibited various forms of misconduct, and which required that all Globe Life employees comply with relevant laws and regulations, purportedly ensuring that the Company would maintain a workplace free from violence, threatening behavior, and illegal drugs. In truth, Globe Life was engaged in wide-spread insurance fraud, therefore inflating Globe Life’s financial results. In addition, Globe Life permitted a culture of unchecked sexual harassment, in direct contravention of the Company’s Code of Conduct. As a result of defendants’ misrepresentations, shares of Globe Life common stock traded at artificially inflated prices throughout the Class Period.

Class Period

5/8/19 - 4/10/24

Deadline

July 1 2024

Learn More

46

Days Left

EQIX

Equinix, Inc.

Deadline

July 1 2024

Class Period

5/3/19 - 3/24/24

Allegations

(1) Equinix manipulated its financials to reduce operational expenses and boost Adjusted Funds From Operations (“AFFO”); (2) Equinix oversold power capacity and did not warn of the risks associated with this practice; (3) Equinix lacked adequate internal controls; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

5/3/19 - 3/24/24

Deadline

July 1 2024

Learn More

50

Days Left

AXTI

AXT, Inc.

Deadline

July 5 2024

Class Period

3/24/21 - 4/3/24

Allegations

(1) AXT, Inc. overstated its property holdings; (2) the Company did not disclose that the attempted listing of an AXT, Inc. subsidiary in China had reportedly failed; (3) AXT, Inc. routinely engaged in environmental violations and unsafe business practices; (4) AXT, Inc.’s production declined in 2023; and (5) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

3/24/21 - 4/3/24

Deadline

July 5 2024

Learn More

50

Days Left

ALT

Altimmune, Inc.

Deadline

July 5 2024

Class Period

12/1/23 - 4/26/24

Allegations

(i) Altimmune overstated the potential for its lead product candidate, pemvidutide, to stand out from competing glucagon-like peptide-1 agonists based on the drug’s efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

12/1/23 - 4/26/24

Deadline

July 5 2024

Learn More

54

Days Left

LI

Li Auto Inc.

Deadline

July 9 2024

Class Period

2/26/24 - 3/20/24

Allegations

(i) Li Auto had overstated the demand for its vehicles and the efficacy of its operating strategy in launching its battery electric minivan, Li MEGA; (ii) accordingly, the Company was unlikely to meet its Q1 2024 vehicle deliveries estimate; (iii) the foregoing, once revealed, was likely to have a material negative impact on the Company’s financial condition; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/26/24 - 3/20/24

Deadline

July 9 2024

Learn More

57

Days Left

NARI

Inari Medical, Inc.

Deadline

July 12 2024

Class Period

2/23/22 - 2/28/24

Allegations

(i) the Company deceived the investing public, including plaintiff; (ii) cause the market price of Inari common stock to trade above its true value; and (iii) cause plaintiff as well as other class members to purchase or otherwise acquire Inari common stock at artificially inflated prices that did not reflect the stock’s true value during the class period. In furtherance of their unlawful scheme, plan, or course of conduct, defendants took the actions alleged herein.

Class Period

2/23/22 - 2/28/24

Deadline

July 12 2024

Learn More

57

Days Left

SPT

Sprout Social, Inc.

Deadline

July 12 2024

Class Period

11/2/23 - 5/2/24

Allegations

(1) the Company’s sales and revenue growth were not indicative of the Company’s growth as it transitioned to an enterprise sales cycle; (2) the Company faced integration challenges with its acquisition of Tagger, a leading influencer marketing and social intelligence platform; (3) as a result, the Company was “self inducing sales headwinds;” (4) as a result, the Company would revise fiscal year 2024 revenue guidance; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/2/23 - 5/2/24

Deadline

July 12 2024

Learn More

60

Days Left

UNH

UnitedHealth Group Inc.

Deadline

July 15 2024

Class Period

3/14/22 - 2/27/24

Allegations

According to the filed complaint, defendants made false statements and/or concealed that: In truth, UnitedHealth never established proper firewalls between it's complementary businesses, Optum and UnitedHealthcare as required by its own policy, and as it told the court in the antitrust action, the DOJ and investors it would do. Firewalls were never properly created for certain business applications. Despite assurances to the contrary, there was never a meaningful technological separation between Optum and UnitedHealthcare that prevented the sharing of customer sensitive information.

Class Period

3/14/22 - 2/27/24

Deadline

July 15 2024

Learn More

View All Deadlines

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

Levi & Korsinsky Ranked Among the Top 50 Plaintiffs' Firms of 2023
Levi & Korsinsky (“L&K”) has once again been recognized by Institutional Shareholder Services Securities Class Action Services (“ISS SCAS”) as one of the top 50 plaintiffs’ firms in the United States, recovering over $133 million for investors in securities-related class action settlements in 2023. On April 22, 2024, ISS SCAS released its “Top Plaintiff Law...Read more

May 14, 2024

Learn More

Lantronix, Inc. Lawsuit Proceeds with Selection of Co-Lead Plaintiffs
Neilsen v. Lantronix, Inc., et al., 8:24-cv-00385-FWS-JDE is a lawsuit currently pending in the United States District Court for the Central District of California. The action was filed on behalf of investors in Lantronix, Inc. (NASDAQ: LTRX) who allegedly suffered losses due to securities fraud by the company. On May 7, 2024, United States District...Read more

May 13, 2024

Learn More

Lead Plaintiffs Appointed in AST SpaceMobile, Inc. Stockholders Litigation
Levi & Korsinsky, LLP recently filed a class action lawsuit  on behalf of current and former stockholders in AST SpaceMobile, Inc. (NASDAQ:ASTS) who allegedly suffered losses due to the merger of New Providence Acquisition Corporation and AST & Science, LLC in April 2021. The lawsuit (In re AST SpaceMobile, Inc. Stockholders Litigation, Consolidated C.A. No....Read more

May 10, 2024

View All News

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys